The stimulation of new collagen is the goal of many aesthetic procedures currently used on the market. However, what Koreans have introduced to Europe together with Fillmed—one of the most well-known manufacturers of aesthetic medical products in France—is already being described by many professionals as an exceptional product on the market.
Juvelook and Lenisna have been developed using a unique technology that enabled the combination of poly-D,L-lactic acid (PDLLA) and non-crosslinked hyaluronic acid within a single formula—two components which, when acting together, stimulate the production of collagen and elastin. In addition, the interaction of these two components helps protect the collagen present in the skin, which is particularly relevant for the care of mature skin showing signs of aging.
Collagen is an important structural component of the skin, the amount of which naturally begins to decrease from approximately the age of 25. Moreover, collagen levels in the skin are reduced due to external factors such as UV radiation, pollution, lifestyle, and nutrition. Collagen deficiency in the skin is easy to recognize—it is manifested by sagging, withered skin that has lost firmness and volume, and whose overall condition reflects advanced aging processes.
Collagen biostimulators used on the market act through different mechanisms—some provide too weak stimulation, while others, on the contrary, produce excessively rapid and strong stimulation, which may result in skin scarring. JUVELOOK and LENISNA are products that are well regarded for their ability to stimulate gradual and moderate collagen production, thus providing the skin with a strong, yet not overly sudden, controlled firming effect. This is determined by the distinctive composition of the product: it contains one of the highest PDLLA concentrations on the market (85%), and due to the unique structure of the particles of this ingredient, it is well tolerated by the skin.
It is also important to note that, despite the presence of hyaluronic acid in the composition, these products do not contour mechanically and do not provide volume in the same way as hyaluronic acid fillers; therefore, the rejuvenating results are highly natural, without the scenario of altered facial features.
Who is it suitable for?
The JUVELOOK® product is most commonly applied to patients with the first signs of aging, especially in cases of reduced elasticity, skin laxity, and the resulting changes in the facial contour. This product is also used for emerging first wrinkles, skin with enlarged pores, atrophic acne scars, pigmentation, and poor skin tone.
The LENISNA® product is most commonly applied to patients with advanced signs of aging, clearly sagging skin, and when the face begins to lack natural structural volume. It can also be used for the body: for sagging skin of the arms and knees, the buttocks, and for the correction of stretch marks.
Both products are certified as injectable, therefore procedures may only be performed by dermatologists and plastic surgeons.
The injected product begins to act immediately; however, results become visible in approximately 2–4 weeks, during which the appearance of the skin gradually improves, becoming more even, firmer, and more radiant.
How many procedures are required?
JUVELOOK standard protocol – 3 procedures every 6 weeks, with maintenance procedures performed after 1–1.5 years.
LENISNA standard protocol – 3 procedures every 8 weeks, with maintenance procedures performed after 1–2 years.
These procedures may also be combined with the Fillmed NCTF-135 HA product, which additionally enhances the effect of improving skin quality.
Who are JUVELOOK and LENISNA procedures not suitable for?
Juvelook and Lenisna procedures are not recommended during pregnancy and breastfeeding, as well as in the presence of active skin infections or inflammatory processes at the injection site. The procedure should not be performed on patients with autoimmune diseases or immune system disorders, as well as in cases of a tendency to form keloid or hypertrophic scars. Caution is also applied to patients with bleeding disorders or those taking anticoagulants. The procedures are not suitable in cases of hypersensitivity to the components or active-stage oncological diseases.
The final decision regarding the suitability of the procedure in all cases is made by the physician after evaluating the individual condition of the patient.
